Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.

LATEST PRESS RELEASES

17 November 2020

The Subscription Period for the Warrants of Series TO1 in Stayble Therapeutics AB begins Today October 17, 2020

Today is the first day of exercise TO1 for subsription to company shares that extend to December 1, 2020. Every one warrent gives the right to subscribe one new share in the Company to an exercise pri...

16 November 2020 Regulatory

The Exercise Price for the Warrants of Series TO1 in Stayble Therapeutics AB has been set to SEK 12,30

Stayble Theraputics AB carried out during the first quarter of 2020 in conection with the listing on Nasdaq First North Growt Market, an issue of units where one unit consisted of one newly issued sha...

FINANCIAL CALENDAR

Interim report Q4 2020
15February2021